Teva gains $400M investment from Blackstone Life Sciences to advance duvakitug
Source: SeekingAlpha
2026-03-03 17:32:49 ET
More on Teva Pharmaceutical
- Teva Pharmaceutical Industries Limited (TEVA) Discusses Duvakitug IBD Phase 2b Maintenance Top-Line Results - Slideshow
- Teva Pharmaceutical Industries Limited (TEVA) Discusses Duvakitug IBD Phase 2b Maintenance Top-Line Results Transcript
- Teva Pharmaceutical Industries Limited (TEVA) Q4 2025 Earnings Call Transcript
- Teva, Medincell granted FDA review for long-acting antipsychotic
- Corcept falls as appeals court sides with Teva in Korlym patent dispute
Read the full article on Seeking Alpha
For further details see:
Teva gains $400M investment from Blackstone Life Sciences to advance duvakitug
Teva Pharmaceutical Industries Limited American Depositary Shares
NASDAQ: TEVA
TEVA Trading
2.24% G/L:
$31.515 Last:
3,064,647 Volume:
$31.38 Open:
TEVA Latest News
TEVA Stock Data
$39,421,335,208
1,138,314,769
0.04%
264
N/A
Pharmaceuticals
Healthcare
IL
Tel Aviv
